Literature DB >> 1987352

Survival differences in patients with AIDS.

G H Friedland1, B Saltzman, J Vileno, K Freeman, L K Schrager, R S Klein.   

Abstract

To define the clinical, demographic, and behavioral variables that may influence survival in patients with AIDS, we studied 526 patients with AIDS diagnosed through September 1987 who were cared for at a single medical center. A diversity of racial and ethnic backgrounds, ages, both men and women, and all risk behaviors except hemophilia were well represented. The initial AIDS defining diagnosis was the most powerful predictor of survival. The median survival was 12.8 months for patients presenting with Kaposi's sarcoma (p less than 0.001), 10.9 months for patients presenting with Pneumocystis carinii pneumonia (p less than 0.001), and 4.8 months for patients presenting with other infections or neoplasms (p less than 0.02). For the entire series, male sex and younger age were associated with more favorable survival (p less than 0.025). For those presenting with Pneumocystis carinii pneumonia, in addition to younger age (p less than 0.025), black race (p less than 0.025) and the combination of male sex and intravenous drug use (p less than 0.005) were associated with a more favorable survival. Within a setting of comparable clinical care, survival from the point of diagnosis of AIDS is associated most strongly with the initial AIDS diagnosis, but differences in age, gender, race, and risk behavior also exert an influence on survival.

Entities:  

Mesh:

Year:  1991        PMID: 1987352

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  19 in total

1.  Prognostic factors correlated with survival in AIDS patients.

Authors:  S Casari; A Donisi; G Paraninfo; D Tomasoni; L Palvarini; P Nasta; A Bergamasco; G P Cadeo; G Carosi
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

2.  Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001.

Authors:  Girma Woldemichael; Demian Christiansen; Sandra Thomas; Nanette Benbow
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

3.  Health-related quality of life of HIV-infected women: evidence for the reliability, validity and responsiveness of the Medical Outcomes Study Short-Form 20.

Authors:  M Y Smith; J Feldman; P Kelly; J A DeHovitz; K Chirgwin; H Minkoff
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

4.  Race and the treatment of cytomegalovirus retinitis in a cohort of patients with acquired immunodeficiency syndrome.

Authors:  A K Wutoh; J Hidalgo; J Bareta; W Rhee; R Beardsley; S Steidl
Journal:  J Natl Med Assoc       Date:  1998-04       Impact factor: 1.798

5.  HIV and the black community: the role of the National Medical Association.

Authors:  M K Rawlings; R Lewis
Journal:  J Natl Med Assoc       Date:  1997-10       Impact factor: 1.798

Review 6.  Exercise and human immunodeficiency virus (HIV-1) infection.

Authors:  D Lawless; C G Jackson; J E Greenleaf
Journal:  Sports Med       Date:  1995-04       Impact factor: 11.136

7.  Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia.

Authors:  C E Bush; R M Donovan; N Markowitz; D Baxa; P Kvale; L D Saravolatz
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

Review 8.  Race and survival time with AIDS: a synthesis of the literature.

Authors:  J R Curtis; D L Patrick
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

9.  Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.

Authors:  Mhairi Maskew; Alana T Brennan; Daniel Westreich; Lynne McNamara; A Patrick MacPhail; Matthew P Fox
Journal:  J Womens Health (Larchmt)       Date:  2013-01-25       Impact factor: 2.681

10.  The underrecognition of HIV infection in women in an inner-city emergency room.

Authors:  E E Schoenbaum; M P Webber
Journal:  Am J Public Health       Date:  1993-03       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.